William Blair Has Negative Outlook for ZVRA FY2024 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – William Blair dropped their FY2024 earnings estimates for Zevra Therapeutics in a research note issued to investors on Wednesday, November 13th. William Blair analyst S. Corwin now anticipates that the company will post earnings of ($2.00) per share for the year, down from their prior estimate of ($1.58). William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.92) per share. William Blair also issued estimates for Zevra Therapeutics’ Q4 2024 earnings at ($0.42) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.70) EPS.

A number of other analysts have also recently commented on ZVRA. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research report on Monday, September 30th. Guggenheim assumed coverage on shares of Zevra Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $20.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Zevra Therapeutics in a research note on Friday, October 11th. Maxim Group lifted their target price on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. Finally, JMP Securities initiated coverage on Zevra Therapeutics in a research note on Tuesday, September 24th. They set an “outperform” rating and a $17.00 price target on the stock. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zevra Therapeutics currently has an average rating of “Buy” and a consensus price target of $21.00.

Zevra Therapeutics Stock Performance

NASDAQ ZVRA opened at $8.97 on Monday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $9.21. The business has a fifty day moving average of $8.06 and a 200-day moving average of $6.54. The stock has a market cap of $478.78 million, a price-to-earnings ratio of -4.55 and a beta of 1.93.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same quarter in the prior year, the firm earned ($0.40) earnings per share.

Hedge Funds Weigh In On Zevra Therapeutics

A number of large investors have recently bought and sold shares of the stock. Barclays PLC increased its holdings in shares of Zevra Therapeutics by 292.6% during the 3rd quarter. Barclays PLC now owns 57,599 shares of the company’s stock worth $399,000 after buying an additional 42,926 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Zevra Therapeutics by 14.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock worth $7,246,000 after purchasing an additional 129,600 shares during the period. XTX Topco Ltd purchased a new stake in shares of Zevra Therapeutics during the 3rd quarter worth about $94,000. State Street Corp increased its position in Zevra Therapeutics by 7.4% during the 3rd quarter. State Street Corp now owns 772,825 shares of the company’s stock worth $5,363,000 after purchasing an additional 52,966 shares in the last quarter. Finally, Vestal Point Capital LP purchased a new position in Zevra Therapeutics in the third quarter valued at approximately $3,644,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.